{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:48:48Z","timestamp":1783993728595,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,8,23]],"date-time":"2010-08-23T00:00:00Z","timestamp":1282521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Platinum-based drugs, such as cisplatin and oxaliplatin, are well-known for inducing chronic sensory neuropathies but their acute and motor neurotoxicities are less well characterised. Use was made of nerve conduction studies and needle electromyography (EMG) to assess motor nerve excitability in cancer patients during their first treatment cycle with platinum-based chemotherapy in this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Twenty-nine adult cancer patients had a neurophysiological assessment either before oxaliplatin plus capecitabine, on days 2 to 4 or 14 to 20 after oxaliplatin plus capecitabine, or on days 2 to 4 after carboplatin plus paclitaxel or cisplatin, undertaken by a neurophysiologist who was blinded to patient and treatment details. Patients completed a symptom questionnaire at the end of the treatment cycle.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Abnormal spontaneous high frequency motor fibre action potentials were detected in 100% of patients (n = 6) and 72% of muscles (n = 22) on days 2 to 4 post-oxaliplatin, and in 25% of patients (n = 8) and 13% of muscles (n = 32) on days 14 to 20 post-oxaliplatin, but in none of the patients (n = 14) or muscles (n = 56) tested prior to oxaliplatin or on days 2 to 4 after carboplatin plus paclitaxel or cisplatin. Repetitive compound motor action potentials were less sensitive and less specific than spontaneous high frequency motor fibre action potentials for detection of acute oxaliplatin-induced motor nerve hyperexcitability but were present in 71% of patients (n = 7) and 32% of muscles (n = 32) on days 2 to 4 after oxaliplatin treatment. Acute neurotoxicity symptoms, most commonly cold-induced paraesthesiae and jaw or throat tightness, were reported by all patients treated with oxaliplatin (n = 22) and none of those treated with carboplatin plus paclitaxel or cisplatin (n = 6).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Abnormal spontaneous high frequency motor fibre activity is a sensitive and specific endpoint of acute oxaliplatin-induced motor nerve hyperexcitability, detectable on EMG on days 2 to 4 post-treatment. Objective EMG assessment of motor nerve excitability could compliment patient-reported symptomatic endpoints of acute oxaliplatin-induced neurotoxicity in future studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-10-451","type":"journal-article","created":{"date-parts":[[2010,8,24]],"date-time":"2010-08-24T06:16:41Z","timestamp":1282630601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability"],"prefix":"10.1186","volume":"10","author":[{"given":"Andrew","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritha","family":"Hanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Damianovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"McKeage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,23]]},"reference":[{"key":"2250_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007, 7: 573-584. 10.1038\/nrc2167.","journal-title":"Nat Rev Cancer"},{"key":"2250_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1056\/NEJM199001113220210","volume":"322","author":"JE Mollman","year":"1990","unstructured":"Mollman JE: Cisplatin neurotoxicity. N Engl J Med. 1990, 322: 126-127. 10.1056\/NEJM199001113220210.","journal-title":"N Engl J Med"},{"key":"2250_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","volume":"30","author":"A Grothey","year":"2003","unstructured":"Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003, 30: 5-13. 10.1016\/S0093-7754(03)00399-3.","journal-title":"Semin Oncol"},{"key":"2250_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00002018-199513040-00003","volume":"13","author":"MJ McKeage","year":"1995","unstructured":"McKeage MJ: Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995, 13: 228-244. 10.2165\/00002018-199513040-00003.","journal-title":"Drug Saf"},{"key":"2250_CR5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","volume":"20","author":"RH Wilson","year":"2002","unstructured":"Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002, 20: 1767-1774. 10.1200\/JCO.2002.07.056.","journal-title":"J Clin Oncol"},{"key":"2250_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/mus.10559","volume":"29","author":"TJ Lehky","year":"2004","unstructured":"Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK: Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004, 29: 387-392. 10.1002\/mus.10559.","journal-title":"Muscle Nerve"},{"key":"2250_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/ana.410380505","volume":"38","author":"P Shillito","year":"1995","unstructured":"Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, Vandenberg RJ, Plomp JJ, Vankempen GTH, Chauplannaz G, Wintzen AR, et al: Acquired neuromyotonia - evidence for autoantibodies directed against K+ channels of peripheral-nerves. Annals of Neurology. 1995, 38: 714-722. 10.1002\/ana.410380505.","journal-title":"Annals of Neurology"},{"key":"2250_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/sj.bjp.0706407","volume":"146","author":"RG Webster","year":"2005","unstructured":"Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005, 146: 1027-1039. 10.1038\/sj.bjp.0706407.","journal-title":"Br J Pharmacol"},{"key":"2250_CR9","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1093\/brain\/awp219","volume":"132","author":"SB Park","year":"2009","unstructured":"Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC: Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009, 132: 2712-2723. 10.1093\/brain\/awp219.","journal-title":"Brain"},{"key":"2250_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","volume":"406","author":"H Adelsberger","year":"2000","unstructured":"Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C: The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000, 406: 25-32. 10.1016\/S0014-2999(00)00667-1.","journal-title":"Eur J Pharmacol"},{"key":"2250_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-5751-8-2","volume":"8","author":"A Broomand","year":"2009","unstructured":"Broomand A, Jerremalm E, Yachnin J, Ehrsson H, Elinder F: Oxaliplatin neurotoxicity--no general ion channel surface-charge effect. J Negat Results Biomed. 2009, 8: 2-10.1186\/1477-5751-8-2.","journal-title":"J Negat Results Biomed"},{"key":"2250_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/(SICI)1097-4598(199609)19:9<1127::AID-MUS7>3.3.CO;2-E","volume":"19","author":"JG VanDijk","year":"1996","unstructured":"VanDijk JG, Lammers GJ, Wintzen AR, Molenaar PC: Repetitive CMAPs: Mechanisms of neural and synaptic genesis. Muscle & Nerve. 1996, 19: 1127-1133.","journal-title":"Muscle & Nerve"},{"key":"2250_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ana.410110603","volume":"11","author":"AG Engel","year":"1982","unstructured":"Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN: A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Annals of Neurology. 1982, 11: 553-569. 10.1002\/ana.410110603.","journal-title":"Annals of Neurology"},{"key":"2250_CR14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","volume":"6","author":"TJ Postma","year":"1995","unstructured":"Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann Oncol. 1995, 6: 489-494.","journal-title":"Ann Oncol"},{"key":"2250_CR15","doi-asserted-by":"publisher","first-page":"6359","DOI":"10.1158\/1078-0432.CCR-07-0660","volume":"13","author":"L Gamelin","year":"2007","unstructured":"Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne LB, Gilles S, Boisdron-Celle M, Gamelin E: Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clinical Cancer Research. 2007, 13: 6359-6368. 10.1158\/1078-0432.CCR-07-0660.","journal-title":"Clinical Cancer Research"},{"key":"2250_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1054\/bjoc.1999.1026","volume":"82","author":"D Screnci","year":"2000","unstructured":"Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC: Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer. 2000, 82: 966-972. 10.1054\/bjoc.1999.1026.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-451.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-451\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-451.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:13:30Z","timestamp":1630613610000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,23]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-451","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,23]]},"assertion":[{"value":"28 March 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"451"}}